A causal role for TRESK loss of function in migraine mechanisms

Pettingill, P. et al. (2019) A causal role for TRESK loss of function in migraine mechanisms. Brain, 142(12), pp. 3852-3867. (doi: 10.1093/brain/awz342) (PMID:31742594) (PMCID:PMC6906598)

204055.pdf - Published Version
Available under License Creative Commons Attribution.



The two-pore potassium channel, TRESK has been implicated in nociception and pain disorders. We have for the first time investigated TRESK function in human nociceptive neurons using induced pluripotent stem cell-based models. Nociceptors from migraine patients with the F139WfsX2 mutation show loss of functional TRESK at the membrane, with a corresponding significant increase in neuronal excitability. Furthermore, using CRISPR-Cas9 engineering to correct the F139WfsX2 mutation, we show a reversal of the heightened neuronal excitability, linking the phenotype to the mutation. In contrast we find no change in excitability in induced pluripotent stem cell derived nociceptors with the C110R mutation and preserved TRESK current; thereby confirming that only the frameshift mutation is associated with loss of function and a migraine relevant cellular phenotype. We then demonstrate the importance of TRESK to pain states by showing that the TRESK activator, cloxyquin, can reduce the spontaneous firing of nociceptors in an in vitro human pain model. Using the chronic nitroglycerine rodent migraine model, we demonstrate that mice lacking TRESK develop exaggerated nitroglycerine-induced mechanical and thermal hyperalgesia, and furthermore, show that cloxyquin conversely is able to prevent sensitization. Collectively, our findings provide evidence for a role of TRESK in migraine pathogenesis and its suitability as a therapeutic target.

Item Type:Articles
Additional Information:This project was supported by StemBANCC funding from the Innovative Medicines Initiative Joint Undertaking under Grant Agreement Number 115439, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007e2013) and EFPIA companies in kind contribution. The work was also supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC) and Wellcome Trust (203141/Z/16/Z). This work was also supported by funding from the National Health and Medical Research Council (NHMRC) Australia.
Glasgow Author(s) Enlighten ID:Weir, Dr Gregory
Authors: Pettingill, P., Weir, G. A., Wei, T., Wu, Y., Flower, G., Lalic, T., Handel, A., Duggal, G., Chintawar, S., Cheung, J., Arunasalam, K., Couper, E., Haupt, L. M., Griffiths, L. R., Bassett, A., Cowley, S. A., and Zader, M. Z.
College/School:College of Medical Veterinary and Life Sciences > School of Psychology & Neuroscience
Journal Name:Brain
Publisher:Oxford University Press
ISSN (Online):1460-2156
Published Online:19 November 2019
Copyright Holders:Copyright © 2019 The Authors
First Published:First published in Brain 142(12):3852–3867
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record